Centessa Pharmaceuticals Ownership
| CNTA Stock | USD 17.04 1.15 6.32% |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
Centessa |
Centessa Stock Ownership Analysis
About 93.0% of the company shares are held by institutions such as insurance companies. The book value of Centessa Pharmaceuticals was currently reported as 4.29. The company recorded a loss per share of 1.52. Centessa Pharmaceuticals had not issued any dividends in recent years. Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines to patients. Centessa Pharmaceuticals plc was incorporated in 2020 and is based in Altrincham, the United Kingdom. Centessa Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 68 people. For more info on Centessa Pharmaceuticals PLC please contact Saurabh MD at 44 203 9206789 or go to https://www.centessa.com.Besides selling stocks to institutional investors, Centessa Pharmaceuticals also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Centessa Pharmaceuticals' stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Centessa Pharmaceuticals' strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Centessa Pharmaceuticals Quarterly Liabilities And Stockholders Equity |
|
Centessa Pharmaceuticals Insider Trades History
Only 1.35% of Centessa Pharmaceuticals PLC are currently held by insiders. Unlike Centessa Pharmaceuticals' institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Centessa Pharmaceuticals' private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Centessa Pharmaceuticals' insider trades
Centessa Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Centessa Pharmaceuticals is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Centessa Pharmaceuticals PLC backward and forwards among themselves. Centessa Pharmaceuticals' institutional investor refers to the entity that pools money to purchase Centessa Pharmaceuticals' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Tcg Crossover Management, Llc | 2024-09-30 | 2.9 M | Octagon Capital Advisors Lp | 2024-06-30 | 2.3 M | Artal Group S A | 2024-06-30 | 2.1 M | Driehaus Capital Management Llc | 2024-06-30 | 2.1 M | Farallon Capital Management, L.l.c. | 2024-06-30 | 2 M | Point72 Asset Management, L.p. | 2024-06-30 | 1.8 M | Cormorant Asset Management, Llc | 2024-06-30 | 1.6 M | Deep Track Capital, Lp | 2024-09-30 | 1.4 M | 5am Venture Management, Llc | 2024-06-30 | 1.2 M | Medicxi Ventures Management (jersey) Ltd | 2024-09-30 | 20 M | General Atlantic Llc | 2024-09-30 | 9.7 M |
Centessa Pharmaceuticals Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Centessa Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Centessa Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Centessa Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Centessa Pharmaceuticals Outstanding Bonds
Centessa Pharmaceuticals issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Centessa Pharmaceuticals uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Centessa bonds can be classified according to their maturity, which is the date when Centessa Pharmaceuticals PLC has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
Centessa Pharmaceuticals Corporate Filings
F4 | 15th of November 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
13A | 14th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
8K | 12th of November 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
| 18th of October 2024 Other Reports | ViewVerify |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Centessa Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Centessa Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Centessa Pharmaceuticals Plc Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Centessa Pharmaceuticals Plc Stock:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Centessa Pharmaceuticals PLC. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. You can also try the Portfolio Rebalancing module to analyze risk-adjusted returns against different time horizons to find asset-allocation targets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Centessa Pharmaceuticals. If investors know Centessa will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Centessa Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.52) | Revenue Per Share 0.065 | Return On Assets (0.20) | Return On Equity (0.43) |
The market value of Centessa Pharmaceuticals is measured differently than its book value, which is the value of Centessa that is recorded on the company's balance sheet. Investors also form their own opinion of Centessa Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Centessa Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Centessa Pharmaceuticals' market value can be influenced by many factors that don't directly affect Centessa Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Centessa Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Centessa Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Centessa Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.